Quantcast

Latest liver cancer Stories

2014-09-02 08:30:12

Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular...

2014-08-25 08:28:14

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity,...

2014-08-14 08:29:11

CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street Audience SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in...

obesity and cancer
2014-08-14 07:24:04

redOrbit Staff & Wire Reports - Your Universe Online Obesity increases a person’s risk of developing 10 of the most common forms of cancer, and is believed to cause an estimated 12,000 additional cases of the disease each year, experts from the London School of Hygiene and Tropical Medicine (LSHTM) and the Farr Institute of Health Informatics claim in a new study. The research, which was published online Thursday in the UK medical journal The Lancet, looked at the medical data of...

2014-08-05 08:33:58

POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB: GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells. He also shares insight into the key points that make them different from competitive...

2014-07-29 23:13:49

San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29, 2014 Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and other institutions have identified a combination of pills that cures 9 of 10 hepatitis C patients. The combination of the drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent of patients in 12...

2014-07-28 13:22:50

Cancer Research UK Cancer Research UK scientists at Barts Cancer Institute have found that targeting a molecule in blood vessels can make cancer therapy significantly more effective, according to research published in Nature today (Sunday). The team at Barts Cancer Institute, part of Queen Mary University of London, have found that a molecule, called focal adhesion kinase (FAK), signals the body to repair itself after chemotherapy or radiotherapy, which kill cancer cells by damaging...

2014-07-28 08:29:13

Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as...

2014-07-22 08:31:31

"These positive results enable management to remain optimistic about our ambitious G-202 clinical development program"- Dr. Craig Dionne, CEO SAN ANTONIO, July 22, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and...

2014-07-15 08:28:28

Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5(th) Asia-Pacific Primary Liver...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin